Literature DB >> 2731407

Calcium antagonists in geriatric patients: diltiazem in elderly persons with hypertension.

S C Montamat1, D R Abernethy.   

Abstract

Pharmacodynamics and disposition of diltiazem were determined in twelve young (30 to 39 years of age) and twelve elderly (65 to 83 years of age) persons with hypertension after they had received diltiazem by rapid intravenous and long-term oral administration. Plasma disappearance half-life of diltiazem increased similarly and significantly in both groups with long-term dosing (young: rapid intravenous, 3.7 +/- 0.8 hour; long-term oral, 6.3 +/- 1 hour [mean +/- SE]; elderly: rapid intravenous, 3.8 +/- 0.7 hour; long-term oral, 7.2 +/- 2.1 hour; p less than 0.01). During long-term therapy both systolic and diastolic blood pressure was significantly lowered from baseline beyond a 12-hour dose interval, with greater decreases in systolic blood pressure in the elderly. Heart rate was decreased with long-term therapy in both groups. Maximal prolongation of PR interval was greater in the young after the intravenous dose (young: 46 +/- 28 msec; elderly: 24 +/- 11 msec; p less than .01), but this effect was not seen with long-term therapy. These data demonstrate that diltiazem administered every 12 hours is an effective antihypertensive agent in both young and elderly patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731407     DOI: 10.1038/clpt.1989.90

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Age-related changes in the gastrointestinal system. Effects on drug therapy.

Authors:  F L Iber; P A Murphy; E S Connor
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

Review 4.  Research challenges, new drug development, preclinical and clinical trials in the ageing population.

Authors:  D R Abernethy
Journal:  Drug Saf       Date:  1990       Impact factor: 5.606

Review 5.  Calcium antagonists in the elderly. A risk-benefit analysis.

Authors:  J B Schwartz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

6.  Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses.

Authors:  G Caillé; S Boucher; J Spénard; Z Lakhani; A Russell; J Thiffault; M G Grace
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

Review 7.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

8.  Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension. The Canadian Multicenter Diltiazem-CD Hypertension Trial Group.

Authors:  T D Ruddy; J M Wright; D Savard; S P Handa; A Chockalingam; A P Boulet
Journal:  Cardiovasc Drugs Ther       Date:  1995-06       Impact factor: 3.727

Review 9.  Report of the Canadian Hypertension Society Consensus Conference: 4. Hypertension in the elderly.

Authors:  R A Reeves; J G Fodor; C I Gryfe; C Patterson; J D Spence
Journal:  CMAJ       Date:  1993-09-15       Impact factor: 8.262

10.  A comparative study of the steady-state pharmacokinetics of immediate-release and controlled-release diltiazem tablets.

Authors:  O R Leeuwenkamp; H W Visscher; C K Mensink; J H Jonkman
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.